Search

Displaying results 8161 - 8170 of 9689 in total
  1. Drug

    Rivoglitazone

    go.drugbank.com/drugs/DB09200
    Investigational

    Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes. It is being developed by Daiichi Sankyo Co.

  2. Drug

    Limaprost

    go.drugbank.com/drugs/DB09211
    Investigational

    Prostaglandins have a wide variety of actions, including, but not limited to muscular constriction and mediation of inflammation. … Limaprost alfadex has been shown to improve peripheral circulatory failure with a vasodilator action and an antithrombotic effect.

  3. Drug

    Dexibuprofen

    go.drugbank.com/drugs/DB09213
    ApprovedWithdrawn

    Dexibuprofen, S(+)-ibuprofen, is a non-steroidal anti-inflammatory drug (NSAID). It is a pharmacologically effective enantiomer of racemic ibuprofen that differs in physicochemical properties. … It is proposed to be more pharmacologically active and tolerable with a better safety profile than ibuprofen due to higher concentration of active S enantiomer.

  4. Drug

    Firocoxib

    go.drugbank.com/drugs/DB09217
    ExperimentalVet approved

    Firocoxib is a cycooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug. It currently approved for veterinary use in dogs and horses under the brand names Equioxx and Previcox.

  5. Drug

    Bisoxatin

    go.drugbank.com/drugs/DB09219
    Approved

    Bisoxatin is a stimulant laxative which increases peristalsis and inhibits absorbtion of water and ions in the intestine [L926].

  6. Drug

    Conestat alfa

    go.drugbank.com/drugs/DB09228
    Approved

    C1 Esterase Inhibitor (Recombinant) is a recombinant analogue of endogenous complement component-1 esterase inhibitor (rhC1INH), purified from the milk of transgenic rabbits.

  7. Drug

    Azelnidipine

    go.drugbank.com/drugs/DB09230
    Investigational

    It has a gradual onset of action and produces a long-lasting decrease in blood pressure, with only a small increase in heart rate, unlike some other calcium channel blockers [L1379]. … Azelnidipine is a dihydropyridine calcium channel blocker. It is marketed by Daiichi-Sankyo pharmaceuticals, Inc. in Japan.

    International brands: Rezaltas LD
  8. Drug

    Lacidipine

    go.drugbank.com/drugs/DB09236
    Approved

    Lacidipine is a highly lipophilic molecule that interacts with the biological membranes. … Lacidipine is a lipophilic dihydropyridine calcium antagonist with an intrinsically slow onset of activity.

  9. Drug

    Niguldipine

    go.drugbank.com/drugs/DB09239
    Experimental

    Niguldipine is a calcium channel blocker drug (CCB) with a1-adrenergic antagonist properties.

  10. Drug

    Niludipine

    go.drugbank.com/drugs/DB09240
    Experimental

    Niludipine is a calcium channel blocker.